Document is current

Article History

Received: 5 June 2025

Accepted: 19 August 2025

First Online: 5 September 2025

Declarations

:

: This is a retrospective observational study of data obtained from electronic medical record (EMR) review and an institutional review board-approved prospective database that includes all patients who had PSMA-PET/CT scans and standard-of-care treatment with [177Lu]Lu-PSMA-617 at our institution (DFCI protocol 21–629). The Dana-Farber Harvard Cancer Center IRB waived the requirement for informed written consent. The study was conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments.

: Atish D Choudhury: Advisory board: Tolmar, Pfizer, Astellas, Janssen, Sanofi Aventis; Research Funding to Institution: Bayer, Pfizer, Eli Lilly, Sumitomo Pharma; Honoraria for speaking engagement: Bayer, Pfizer, Lantheus.Mary-Ellen Taplin: Advisory board: Blue Earth Diagnostics, Novartis.Thomas Ng: Unrelated support from Lantheus and Bayer; Supported in part by U.S. National Institutes of Health (R21EB036323, R01DK097112), U.S. Department of Defense (W81XWH-22-1-0061), and the Lee Family Foundation.Praful Ravi: Research funding to institution: Lilly, Bayer, Telix, Blue Earth Diagnostics, Lantheus, Novartis; Advisory Board – Bayer.Heather Jacene: Research Funding to Institution: Blue Earth Diagnostics, Lantheus; Honoraria: Elsevier, intouchCONGRESS, Monrol, ITM; Consulting: Spectrum Dynamics; Royalties: Cambridge Publishing; Stipend: American Journal of Radiology; Supported in part by U.S. National Institutes of Health (R01CA251803, R01Ca235589).All other authors have no disclosures.